TRVI: Trevi Therapeutics Inc Market Capitalization-to-Revenue Ratio
Geopolitical upheavals could disrupt the supply of neurotherapy components and halt trials in restricted regions. The P/S trajectory confirms the impact of these factors on quotes, where the indicator determines the parameter status. Trevi Therapeutics (TRVI) delegates drug synthesis to external contractors, while its promising cough treatments are currently undergoing the final stages of regulatory approval.
Metric breakdowns and analytics for Trevi Pharma (TRVI)
- stock quotes and analyst forecast:
- market capitalization information:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Trevi Therapeutics|TRVI - Long-Term Debt to Equity|Current Liabilities to Equity Trevi Therapeutics|TRVI - Company Aggregate Debts|Debts to Book Value Trevi Therapeutics, Inc.|TRVI - Company Long-Term Liabilities|Company Short-Term Debts Trevi Therapeutics|Intermediate Liquidity Ratio trevitherapeutics.com
- earnings and multiples data:
TRVI - Net Profit|Company Profit Forecast Trevi Therapeutics|TRVI - P/E Multiple|Projected Price to Earnings Trevi Corp|TRVI - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Trevi Therapeutics, Inc.|TRVI - Operating profit before deduction of amortization|Earnings per share for the last four quarters Trevi Therapeutics|TRVI - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months trevitherapeutics.com|TRVI - Net earnings per share growth this year|Net earnings per share growth forecast for next year Trevi Therapeutics
- total revenue and sales volume data:
General company analysis:TRVI - Trevi Pharma
The P/S multiple determines the market value of a business relative to its annual revenue, allowing for an assessment of the premium paid per unit of sales. By analyzing the current P/S of Trevi Therapeutics (TRVI), an investor can identify unjustified speculative growth, which is critical since the operating losses from the development of Haduvio are already priced in, and future value depends on the success of clinical trials.
Who Trevi Therapeutics competes with
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|Praxis Corp - P/S Multiple|Anavex Corp (AVXL) - Market Cap to Revenue|CBLL: P/S Multiple|Prothena Biosciences - Market Capitalization-to-Revenue Ratio|ALEC (alector.com) - P/S Multiple|Market Cap to Revenue Ratio ANNX (Annexon Biosciences)|Price-to-Revenue Ratio Omeros Corporation (OMER)|Neurogene Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio AC Immune S.A. ACIU|Price-to-Revenue Coefficient Voyager Therapeutics (VYGR)|Neumora - P/S Multiple|Price-to-Sales Ratio SCLX|Tevogen Bio Inc. (TVGN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio ACOG|CGTX (cogrx.com) - P/S Multiple|Market Cap to Revenue inhibikase.com (IKT)|Price-to-Revenue Ratio Cassava Sciences Inc (SAVA)|Price-to-Revenue Coefficient Assertio|P/S Multiple COYA (Coya Therapeutics, Inc.)|Market Cap to Sales Volume VTGN (VistaGen Therapeutics Inc)|OVID: Market Cap to Revenue|ABOS: Price-to-Revenue Ratio|CervoMed (CRVO) - Price-to-Revenue Ratio|Price to Sales Alterity Therapeutics Ltd (ATHE)|CLNN (Clene) - P/S Multiple|Market Cap to Revenue Ratio PEPG (PepGen)|Market Cap to Revenue JUNS (Jupiter Neurosciences, Inc.)|P/S Multiple relmada.com (RLMD)|Price-to-Revenue Ratio Annovis Bio Corp ANVS|GRCE: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
